Literature DB >> 15344846

Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters.

Giorgio Poli1, Piera Anna Martino, Stefania Villa, Gabriella Carcassola, Maria Laura Giannino, Paola Dall'Ara, Claudia Pollera, Selina Iussich, Vito M Tranquillo, Silvio Bareggi, Paolo Mantegazza, Wilma Ponti.   

Abstract

Among transmissible spongiform encephalopathies (TSE), particularly dreadful are the bovine spongiform encephalopathy (BSE), because of its epidemic character, and the new variant of Creutzfeldt-lakob disease (vCJD) in man, possibly related to BSE prion, through the intake of infected food. To treat TSE, many potentially therapeutic agents have been tested: some of them, among which is Congo Red (CAS 573-58-0, CR), delayed the onset of symptoms in scrapie-infected rodents, and some CR derivatives proved to be effective in vitro. The capacity of a synthesized CR derivative (CR-A) and of the aromatic central benzidine rings of CR (CR-B) to abrogate scrapie-induced disease in experimentally infected hamsters was assayed. CR, used as reference substance, administered i.c. after pre-incubation with the scrapie inoculum, was strongly effective in slowing the progression of the infection, while both CR-A and CR-B, administered alone or together, were not effective. Both CR-A and CR, when administered by subcutaneous route in i.c. scrapie-infected animals. prolonged the survival time in comparison to controls; CR-B was not effective. Moreover, both CR and CR-A were very effective in prolonging the survival time of i.p. scrapie-infected hamsters. The hypothesis of possible different mechanisms of interaction between CR or CR-A and the scrapie agent related to the chemical structures of the molecules is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15344846     DOI: 10.1055/s-0031-1296992

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.

Authors:  Giorgio Poli; Erica Corda; Piera Anna Martino; Paola Dall'ara; Silvio R Bareggi; Giampietro Bondiolotti; Barbara Iulini; Maria Mazza; Cristina Casalone; Sung Hee Hwang; Bruce D Hammock; Bora Inceoglu
Journal:  Life Sci       Date:  2013-05-05       Impact factor: 5.037

Review 2.  Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy.

Authors:  Karen Vana; Chantal Zuber; Daphne Nikles; Stefan Weiss
Journal:  Cell Mol Neurobiol       Date:  2006-12-07       Impact factor: 5.046

Review 3.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

4.  Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Authors:  Sarah Webb; Tamuna Lekishvili; Corinna Loeschner; Shane Sellarajah; Frances Prelli; Thomas Wisniewski; Ian H Gilbert; David R Brown
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

5.  Styryl-based and tricyclic compounds as potential anti-prion agents.

Authors:  Erika Chung; Frances Prelli; Stephen Dealler; Woo Sirl Lee; Young-Tae Chang; Thomas Wisniewski
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.